From Glioblastoma Treatments
Jump to navigationJump to search
|
|
| (8 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| {{TreatmentInfo
| | |
| |drug_name=Clomipramine
| |
| |FDA_approval=Yes
| |
| |used_for=Depression, Obsessive-compulsive disorder, GBM
| |
| |category=Repurposed Drugs
| |
| |notes=This old FDA-approved drug was first used for the treatment of depression, and now also
| |
| for treatment of obsessive-compulsive neuroses. Its rationale as a treatment for gliomas is
| |
| that it selectively depresses mitochondrial function in glioma cells while leaving normal
| |
| cells unaffected, causing the glioma cells to undergo apoptosis (programmed cell death).
| |
| Reported at the 2005 ASCO meeting (122) was a clinical trial evaluating the outcome of
| |
| its use with 27 patients with high-grade gliomas (the distribution of GBMs vs. grade 3
| |
| tumors was not reported in the abstract, nor was the clinical history of the patients).
| |
| Chlorimipramine was added to their conventional treatment with doses from 25 mg daily
| |
| escalated to 150 mg daily. Median survival was 27 months; 20 of the 27 patients showed
| |
| partial tumor regressions. This appears to be a promising new treatment, although
| |
| additional testing with more detailed reporting of the results is clearly needed. An
| |
| interesting sidelight on chlorimipramine is that laboratory research has shown that it
| |
| strongly potentiates the toxicity of gleevec for glioma cells
| |
| }}
| |
Latest revision as of 08:27, 27 March 2024
